| Variable . | Aβ-negative non-demented (n = 107) . | Aβ-positive non-demented (n = 71) . |
|---|---|---|
| Age (years) | 69.7 ± 5.7 | 72.4 ± 6.2 |
| Female (%) | 51 (47%) | 36 (51%) |
| Education (years) | 16.7 ± 2.5 | 15.7 ± 2.9 |
| APOEɛ4 carriers (%) | 31 (29%) | 35 (49%) |
| MMSE | 28.9 ± 1.1 | 28.3 ± 1.6 |
| CSF sTREM2 (pg/ml) | 3697.6 ± 2039.5 | 3916.9 ± 2301.3 |
| tau-PET follow-up time (years) | 3.0 ± 1.6 | 2.3 ± 1.2 |
| MCI (%) | 60 (56%) | 44 (62%) |
| Variable . | Aβ-negative non-demented (n = 107) . | Aβ-positive non-demented (n = 71) . |
|---|---|---|
| Age (years) | 69.7 ± 5.7 | 72.4 ± 6.2 |
| Female (%) | 51 (47%) | 36 (51%) |
| Education (years) | 16.7 ± 2.5 | 15.7 ± 2.9 |
| APOEɛ4 carriers (%) | 31 (29%) | 35 (49%) |
| MMSE | 28.9 ± 1.1 | 28.3 ± 1.6 |
| CSF sTREM2 (pg/ml) | 3697.6 ± 2039.5 | 3916.9 ± 2301.3 |
| tau-PET follow-up time (years) | 3.0 ± 1.6 | 2.3 ± 1.2 |
| MCI (%) | 60 (56%) | 44 (62%) |
Data are presented as mean ± standard deviation unless specified otherwise.
APOEɛ4, apolipoprotein E genotype (carrying at least one ɛ4 allele); CSF sTREM2, cerebrospinal fluid soluble Triggering Receptor Expressed on Myeloid Cell 2; MMSE, Mini-Mental State Exam; PET, positron emission tomography; MCI, mild cognitive impairment.
| Variable . | Aβ-negative non-demented (n = 107) . | Aβ-positive non-demented (n = 71) . |
|---|---|---|
| Age (years) | 69.7 ± 5.7 | 72.4 ± 6.2 |
| Female (%) | 51 (47%) | 36 (51%) |
| Education (years) | 16.7 ± 2.5 | 15.7 ± 2.9 |
| APOEɛ4 carriers (%) | 31 (29%) | 35 (49%) |
| MMSE | 28.9 ± 1.1 | 28.3 ± 1.6 |
| CSF sTREM2 (pg/ml) | 3697.6 ± 2039.5 | 3916.9 ± 2301.3 |
| tau-PET follow-up time (years) | 3.0 ± 1.6 | 2.3 ± 1.2 |
| MCI (%) | 60 (56%) | 44 (62%) |
| Variable . | Aβ-negative non-demented (n = 107) . | Aβ-positive non-demented (n = 71) . |
|---|---|---|
| Age (years) | 69.7 ± 5.7 | 72.4 ± 6.2 |
| Female (%) | 51 (47%) | 36 (51%) |
| Education (years) | 16.7 ± 2.5 | 15.7 ± 2.9 |
| APOEɛ4 carriers (%) | 31 (29%) | 35 (49%) |
| MMSE | 28.9 ± 1.1 | 28.3 ± 1.6 |
| CSF sTREM2 (pg/ml) | 3697.6 ± 2039.5 | 3916.9 ± 2301.3 |
| tau-PET follow-up time (years) | 3.0 ± 1.6 | 2.3 ± 1.2 |
| MCI (%) | 60 (56%) | 44 (62%) |
Data are presented as mean ± standard deviation unless specified otherwise.
APOEɛ4, apolipoprotein E genotype (carrying at least one ɛ4 allele); CSF sTREM2, cerebrospinal fluid soluble Triggering Receptor Expressed on Myeloid Cell 2; MMSE, Mini-Mental State Exam; PET, positron emission tomography; MCI, mild cognitive impairment.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
